Filing Flows › Companies › Praxis Precision Medicines › Report card
Praxis Precision Medicines earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 4 reports beat the EPS estimate
Praxis Precision Medicines (PRAX) beat the analysts' EPS estimate in 3 of its last 4 reports (75%), by +6.7% on average. On report days the stock moved 2.4% in either direction on median (largest 13.0%), rising 75% of the time; after a beat it rose 67% of the time. Next report: Nov 9, 2026, analysts expect EPS −$3.63.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | GAAP EPS | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|
| Q to Jun 2026 | Aug 6, 2026 | −$3.69 | −$2.87 | +22.2% | −$2.87 | +13.0% | +12.6% |
| Q to Mar 2026 | May 7, 2026 | −$3.68 | −$3.20 | +13.0% | −$3.20 | -2.4% | -2.9% |
| Q to Dec 2025 | Feb 19, 2026 | −$3.13 | −$3.50 | -12.0% | — | +1.9% | +1.5% |
| Q to Sep 2025 | Nov 5, 2025 | −$3.49 | −$3.36 | +3.7% | −$3.36 | +0.3% | +1.1% |
Estimates and reported EPS are the Street's adjusted figures; GAAP EPS is from the filing (SEC XBRL). The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 4 reports the stock moved 2.4% on median on the day (close to close), the largest move 13.0%.
After a beat the stock rose 67% of the time (3 beats).
The next report: what to expect → Praxis Precision Medicines: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.